Radioactive 'Warhead' drug targets tough cancers in first human trial
NCT ID NCT07006727
Summary
This is an early-stage study to test the safety and find the right dose of a new radioactive drug called [225Ac]Ac-ETN029 for adults with advanced cancers that have a protein called DLL3. The trial will also test an imaging version of the drug to see where it goes in the body. Researchers want to see if the treatment is safe and if it shows any signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corewell Health William Beaum Hosp
RECRUITINGRoyal Oak, Michigan, 48073-6769, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 03080, South Korea
-
University Of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.